Updated Phase 2 data point to a 74% progression-free survival rate at 16 months for iSCIB1+ added to ipilimumab plus nivolumab in a selected HLA population, an interim 24-percentage-point improvement versus real-world standard of care and historical benchmarks. The company also reports consistency across PD-L1–low, BRAF wild-type, and prior checkpoint-exposed subgroups.
The core development is regulatory: FDA has cleared an IND for a registrational Phase 3 trial of Scancell’s DNA Immunobody iSCIB1+ in advanced melanoma, with progression-free survival agreed as the primary surrogate endpoint. The decision follows completion of the 140-patient, open-label SCOPE Phase 2 program evaluating SCIB1/iSCIB1+ with checkpoint inhibitors in previously untreated unresectable stage IIIB/IV melanoma. Scancell has selected iSCIB1+ for advancement, administered needle-free intramuscularly, and will enrich enrollment using HLA-based selection that the company says covers roughly 80% of melanoma patients. A Phase 3 start is targeted for 2026, with financing and partnering options under evaluation.
Strategically, this is an additive-play bet on immunization layered atop checkpoint doublet therapy. The enrichment strategy is designed to maximize effect size and control trial economics while keeping screenable prevalence broad enough to support global enrollment. FDA’s acceptance of PFS as a registrational endpoint signals openness to time-to-event surrogates in this setting, potentially shortening timelines and reducing required sample sizes compared with OS-driven designs. The tension is that cross-trial comparisons underpin the Phase 2 narrative, and the field is shifting: many U.S. centers have migrated from nivolumab plus ipilimumab to regimens like nivolumab plus relatlimab to manage toxicity, raising questions about the most defensible control arm in 2026. Triplet strategies also face scrutiny on incremental clinical benefit versus added complexity, cost, and AE management.
For sites, an HLA-enriched Phase 3 implies prescreening logistics, central typing turnaround, and higher screening failure risk that must be budgeted and staffed. Needle-free intramuscular administration will require device training and supply chain coordination alongside standard checkpoint infusion operations. If the control remains ipilimumab plus nivolumab, AE monitoring and inpatient resource utilization could increase; if the control shifts to PD-1/LAG-3, protocol amendments and stratification will be pivotal. CROs should anticipate robust biomarker operations, immunogenicity assays, and adaptive monitoring keyed to PFS events. Regulators will watch for assay reproducibility, lot-to-lot consistency for a plasmid DNA product, and a clear causal link between immune readouts and clinical effect. Payers will likely prioritize OS and durability, making secondary endpoints and quality-of-life data consequential to eventual access discussions.
Key watch items are Phase 3 design specifics: control regimen selection, stratification factors (PD-L1, BRAF, prior checkpoint exposure), event-driven assumptions tied to PFS, and the operational load of HLA screening at scale. The final SCOPE readout, including mature OS and safety in the triplet context, will determine whether the Phase 2 signal survives randomization. Manufacturing readiness for plasmid DNA and consistent device availability are nontrivial execution risks. Financing remains an overhang; a partner with checkpoint footprint and global site networks would de-risk startup and control-arm alignment. The broader market test is whether a targeted DNA vaccine can deliver reproducible, clinically meaningful benefit on top of modern backbones without unacceptable operational drag—particularly as melanoma standards continue to evolve.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
